🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

163 results for “L.” Clear

  1. The bioavailability study of Dapagliflozin

    Laboratorios Tillomed Spain S.L.U

    not applicable (submitted trial is a bioequivalence study

    phase 1 other active

    1 trial

  2. Virus-specific T-cell Immunity for the Treatment of Some Resistant Viral Infections After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)

    Istituto Gentili S.r.l.

    Patients who have received an allogeneic haematopoietic stem cell transplant and who have developed post-transplant viral reactivation (CMV, Adenovirus, EBV) resistant to pharmacological therapies.

    phase 1 other active

    1 trial

  3. Zolmitriptan intranasal.

    BRIGHT MINDS BIOSCIENCES INC.

    Healthy

    phase 1 small molecule completed

    1 trial

  4. BIMERVAX LP.8.1 emulsion for injection COVID-19 Vaccine (recombinant, adjuvanted)

    Hipra Human Health S.L.

    COVID-19

    approved small molecule active

    1 trial

  5. Bilaxten Flas 10 mg comprimidos bucodispersables

    A. Menarini Industrie Farmaceutiche Riunite s.r.l.

    Allergic rhinoconjunctivitis

    approved small molecule active

    1 trial

  6. Clensia polvo para solución oral., CitraFleet Polvo para solución oral en sobre

    The George Institute

    colorectal cancer early detection

    approved small molecule active

    1 trial

  7. Cormeto 250 mg capsule molli

    Istituto Gentili S.r.l.

    patients with adrenal incidentalomas and subclinical/mild Cushing’s syndrome

    approved small molecule active

    1 trial

  8. Humira 40 mg solution for injection in pre-filled pen, ORENCIA 125 mg solution for injection in pre-filled syringe, Enbrel 50 mg solution for injection in pre-filled syringe, Reumaflex 50 mg/ml soluzione iniettabile, siringa preriempita, ORENCIA 250 mg powder for concentrate for solution for infusion, Cosentyx 150 mg solution for injection in pre-filled syringe, Enbrel 25 mg solution for injection in pre-filled syringe, Simponi 45 mg/0.45 mL solution for injection in pre-filled pen., Jylamvo 2 mg/ml oral so

    Istituto Gentili S.r.l.

    Juvenile idiopathic arthritis

    approved small molecule active

    1 trial

  9. INFLIXIMAB, INFLIXIMAB

    Istituto Gentili S.r.l.

    Inflammatory Bowel Disease

    approved small molecule active

    1 trial

  10. Kaftrio 37.5 mg/25 mg/50 mg film-coated tablets, Kalydeco 75 mg film-coated tablets, Kalydeco 150 mg film-coated tablets, Kaftrio 75 mg/50 mg/100 mg film-coated tablets

    Istituto Gentili S.r.l.

    Cystic Fibrosis

    approved small molecule active

    1 trial

  11. L. helveticus R0052 and B. longum R0175

    Acadia Pharmaceuticals B.V.

    Attention Deficit Hyperactivity Disorder

    approved other active

    1 trial

  12. LacTEST 0,45 g polvo para solución oral.

    Lacuna Pharma Pty Ltd

    Lactose intolerance

    approved small molecule active

    1 trial

  13. Morfina cloridrato S.A.L.F. 10 mg/ml soluzione iniettabile, ROPIVACAINA CLORIDRATO BIOINDUSTRIA L.I.M. 10 mg/ml soluzione iniettabile, CATAPRESAN 150 microgrammi/ml soluzione iniettabile

    Istituto Gentili S.r.l.

    cesarean section

    approved small molecule active

    1 trial

  14. Placebo, Desloratadine 5 mg orodispersible tablets, Bactil Flas 10 mg Liofilizados orales, Bilaxten 20 mg comprimidos bucodispersables

    A. Menarini Industrie Farmaceutiche Riunite s.r.l.

    Allergy

    approved small molecule active

    1 trial

  15. RITALINE L.P. 10 mg, gélule à libération prolongée

    Tour Hekla

    Attention Deficit Disorder with or without Hyperactivity (ADHD) is a neurodevelopmental disorder characterized by disabling symptoms of inattention and/or hyperactivity-impulsivity beginning before the age of 12 with significant personal, social, academic and/or occupational impact (American Psychiatric Association 2013). This disorder, whose prevalence is around 5% in children and adolescents, affects 2.6% of adults (American Psychiatric Association 2013; Song et al. 2021).

    approved small molecule active

    1 trial

  16. RIVAROXABAN , RIVAROXABAN, RIVAROXABAN

    Pari Pharma GmbH

    Patients with excessive supraventricular ectopies or short atrial runs (ESVEA) defined as ≥ 1% premature atrial contractions (PAC) /24 hours or any atrial runs ≥ 20 PACs (but shorter than 30 seconds) on a 24-hour Holter ECG monitoring and CHA2DS2VASC score ≥ 3. Patients with any atrial runs ≥ 20 PACs but shorter than 30 seconds on a 15-21 days Holter ECG monitoring and CHA2DS2VASC score ≥ 3 may also be included in the Short-Run trial.

    approved small molecule active

    1 trial

  17. Softacort 3,35 mg/ml colirio en solución en envases unidosis

    Laboratorios Tillomed Spain S.L.U

    Dry Eye and Meibomian Gland Dysfunction

    approved small molecule active

    1 trial

  18. The impact of extra-fine inhalation corticosteroid particles on small-airway disease in Chronic Obstructive Pulmonary Disease (COPD): a randomized, prospective cross-over trial.

    Pierre Fabre Australia Pty Ltd

    Chronic Obstructive Pulmonary Disease

    approved other active

    1 trial

  19. FGFR Inhibitor, IDH1 Inhibitor, HER2 Inhibitor, PARP Inhibitor, BRAF Inhibitor, MEK Inhibitor, ICIs, EGFR-TKIs, NTRK-TKI, and et. al.

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Biliary Tract Neoplasms

    small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources